What Happened
In August 2026, Altimmune initiated the PERFORMA Phase 3 trial, advancing its compound pemvidutide into late-stage testing for liver disease. PERFORMA is a global, randomized, double-blind, placebo-controlled study in adults with metabolic dysfunction-associated steatohepatitis, or MASH, and confirmed moderate-to-advanced liver fibrosis at stage F2 to F3. The launch moves pemvidutide into the pivotal phase of development in an area where treatment options have been limited.
What Pemvidutide Is
Pemvidutide is a once-weekly GLP-1/glucagon dual agonist. It activates two receptors: GLP-1, which supplies the appetite and glucose effects familiar across the incretin field, and glucagon, which is thought to play a particular role in liver-fat reduction. That glucagon component is central to the compound's rationale in liver disease, where reducing hepatic fat is a key therapeutic aim. Pairing glucagon with GLP-1 is a design choice intended to bring an additional metabolic lever to bear on the liver specifically.
The Trial Design
PERFORMA is built to a rigorous standard. It is global, randomized, double-blind, and placebo-controlled, the combination of features that gives a trial the strongest footing for interpreting its results. The enrollment criteria are specific: adults with MASH and confirmed fibrosis in the moderate-to-advanced range, stage F2 to F3. Targeting that fibrosis band matters because fibrosis stage is closely tied to long-term liver outcomes, making it a meaningful population in which to test a candidate. A well-controlled design in a defined, higher-risk group is what allows a Phase 3 study to produce interpretable evidence about whether a compound changes the disease.
The move to Phase 3 rests on earlier work. In Phase 2, pemvidutide showed antifibrotic activity, meaning signals of benefit against the liver scarring that defines advancing MASH. Antifibrotic effects are a demanding endpoint in liver-disease research, and a Phase 2 signal on that measure is part of what justified a large Phase 3 program. Mid-stage antifibrotic signals do not guarantee a confirmatory result, which is precisely why PERFORMA is structured to test the effect rigorously.
The Glucagon Rationale
The glucagon arm of pemvidutide's dual mechanism is thought to help drive liver-fat reduction. Glucagon-receptor activation is associated with increased energy expenditure and effects on hepatic fat metabolism that go beyond what GLP-1 alone provides. In MASH, where liver-fat accumulation is a core feature, that added mechanism is the strategic logic behind pairing glucagon with GLP-1. It places pemvidutide within the broader glucagon/GLP-1 class also being tested through compounds like survodutide and mazdutide.
What It Means
PERFORMA situates pemvidutide within the intensifying effort to bring GLP-1-based compounds to liver disease, a space where effective therapies have been scarce. The trial's design and its focus on moderate-to-advanced fibrosis make it a meaningful test of whether the dual GLP-1/glucagon approach can deliver on its antifibrotic promise in a rigorously controlled setting. Its results will contribute to the growing evidence base on how incretin-based dual agonists perform against liver fibrosis.
Important Note
This article is for educational and research reference purposes only. It does not provide dosing advice for human use. Peptide compounds discussed here are sold for research purposes, and nothing here constitutes medical advice. Approved medications should only be used under physician supervision.